Why Did H.C. Wainwright Give Cassava Sciences Inc (SAVA) Stock Neutral Rating?
H.C. Wainwright has recently reduced Cassava Sciences Inc (SAVA) stock to Neutral rating, as announced on July 1, 2024, according to Finviz. Earlier, on November 16, 2022, B. Riley Securities had reduced the stock from a Buy to Neutral, setting a price target of $44. Cantor Fitzgerald also reduced Neutral rating with a price target […]
What Factors Have Led to Cassava Sciences Inc (SAVA) Stock Trading -36.71% Below Its 52-Week High?
H.C. Wainwright has recently reduced Cassava Sciences Inc (SAVA) stock to Neutral rating, as announced on July 1, 2024, according to Finviz. Earlier, on November 16, 2022, B. Riley Securities had reduced the stock from a Buy to Neutral, setting a price target of $44. Cantor Fitzgerald also reduced Neutral rating with a price target […]
Cassava Sciences Inc (SAVA) Stock: Greater Than Its Current Valuation?
H.C. Wainwright has recently reduced Cassava Sciences Inc (SAVA) stock to Neutral rating, as announced on July 1, 2024, according to Finviz. Earlier, on November 16, 2022, B. Riley Securities had reduced the stock from a Buy to Neutral, setting a price target of $44. Cantor Fitzgerald also reduced Neutral rating with a price target […]
Uncover the Reason: Why Cassava Sciences Inc (SAVA) Stock Is Trading 239.48% Above Its 52-Week Low?
H.C. Wainwright has recently reduced Cassava Sciences Inc (SAVA) stock to Neutral rating, as announced on July 1, 2024, according to Finviz. Earlier, on November 16, 2022, B. Riley Securities had reduced the stock from a Buy to Neutral, setting a price target of $44. Cantor Fitzgerald also reduced Neutral rating with a price target […]
Why Did Cassava Sciences Inc (SAVA) Stock See 31.75% Surge in the Last 90 Days?
H.C. Wainwright has recently reduced Cassava Sciences Inc (SAVA) stock to Neutral, as announced on July 1, 2024 according to Finviz. Earlier, on November 16, 2022, B. Riley Securities had reduced the stock from a Buy to Neutral, setting a price target of $44 Cantor Fitzgerald also downgraded from Overweight to Neutral rating with a […]
What’s Causing Cassava Sciences Inc (SAVA) Stock’s 16.04% Jump Over the Last Six Months?
H.C. Wainwright has recently reduced Cassava Sciences Inc (SAVA) stock to Neutral, as announced on July 1, 2024 according to Finviz. Earlier, on November 16, 2022, B. Riley Securities had reduced the stock from a Buy to Neutral, setting a price target of $44 Cantor Fitzgerald also downgraded from Overweight to Neutral rating with a […]
Cassava Sciences Inc (SAVA) Posted – Profit Margin Last Year—Can It Hold Up?
H.C. Wainwright has recently reduced Cassava Sciences Inc (SAVA) stock to Neutral, as announced on July 1, 2024 according to Finviz. Earlier, on November 16, 2022, B. Riley Securities had reduced the stock from a Buy to Neutral, setting a price target of $44 Cantor Fitzgerald also downgraded from Overweight to Neutral rating with a […]
Cassava Sciences’ (SAVA) Stock Soars Amid Legal Resolution: Will the Momentum Last?
Cassava Sciences, Inc. (SAVA), a clinical-stage biotechnology firm specializing in the fight against neurodegenerative diseases, saw a dramatic surge in its stock price on Monday. By 3:05 PM EDT, shares had jumped by an impressive +41.50%, reaching $41.19. This significant increase follows the company’s decision to end its defamation lawsuit against four short sellers who […]
Why Cassava Sciences Inc (NASDAQ:SAVA) Stock up 89.75% in Last Week?
H.C. Wainwright raised the price target for the Cassava Sciences Inc (NASDAQ:SAVA) stock from “a Buy” to “a Neutral”. The rating was released on July 01, 2024, according to finviz. The research report from Cantor Fitzgerald has downgraded the stock from Overweight to Neutral, with a price target set at $100. The stock was reiterated […]
The idea of catching Cassava Sciences Inc (SAVA) Stock might be a good one
H.C. Wainwright raised the price target for the Cassava Sciences Inc (NASDAQ:SAVA) stock from “a Buy” to “a Neutral”. The rating was released on July 01, 2024, according to finviz. The research report from Cantor Fitzgerald has downgraded the stock from Overweight to Neutral, with a price target set at $100. The stock was reiterated […]
